Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00299494 (Clinical Trial / inotuzumab ozogamycin / CMC-544)

Study Title
Study Evaluating CMC-544 Administered In Combination With Rituximab In Subjects With Non-Hodgkin’s Lymphoma (NHL) (NCT00299494)

Trial Description
The purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of CMC-544 in combination with rituximab in subjects with follicular, diffuse large B-Cell, or mantle cell NHL. This trial is sponsored by UCB Pharma/ Pfitzer. [1]

Study Data

  • Condition: B-Cell Lymphoma
  • Interventions:
    • Drugs used in this trial
      • inotuzumab ozogamicin (CMC-544)
  • Phase: I& II
  • Enrollment: 119
  • Start: May 2006
  • Completion: June 2014
  • Last verified: August 2014

Study Schematic 

NCT00299494 (Clinical Trial / inotuzumab ozogamycin / CMC-544)

Click here to Return to Drug map


Last Editorial review: July 29, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar